<div id="readability-page-1"><div><p>On January 30, 2026, Amgen Inc. entered into a Termination Agreement with Kyowa Kirin Co. Ltd. pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the &#34;License and Collaboration Agreement&#34;). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory approval.</p><p>The foregoing description of the Termination Agreement and the termination of the License and collaboration agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.</p></div></div>

<p>安进公司已与协和发酵株式会社签署终止协议，以终止自 2021 年 6 月 1 日起生效的许可与合作协议。该终止将在获得监管批准后生效。终止协议的详细信息已在附件 10.1 中列出，供完整性参考</p>

Amgen Inc. Enters into A Termination Agreement with Kyowa Kirin Co., Ltd

marketscreener

Kyowa Kirin Co., Ltd.

Invesco Nasdaq Biotechnology ETF

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

安进

安进公司与协和麒麟株式会社达成终止协议